These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35453212)

  • 1. Clinical Outcomes and Adverse Effects in Septic Patients with Impaired Renal Function Who Received Different Dosages of Cefoperazone-Sulbactam.
    Tai CH; Tang HJ; Lee CH
    Antibiotics (Basel); 2022 Mar; 11(4):. PubMed ID: 35453212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness of cefoperazone-sulbactam vs. piperacillin-tazobactam for the treatment of pneumonia in elderly patients.
    Huang CT; Chen CH; Chen WC; Wang YT; Lai CC; Fu PK; Kuo LK; Chen CM; Fang WF; Tu CY; Ku SC
    Int J Antimicrob Agents; 2022 Jan; 59(1):106491. PubMed ID: 34871744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cefoperazone/sulbactam in critically Ill thrombotic thrombocytopenic purpura patients undergoing therapeutic plasma exchange.
    Li H; Gao C; Lin L; Zhang G; Fan S; Hai X
    J Clin Pharm Ther; 2022 Aug; 47(8):1232-1239. PubMed ID: 35347732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of commonly used antimicrobial susceptibility testing methods for evaluating susceptibilities of clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli to cefoperazone-sulbactam.
    Jean SS; Liao CH; Sheng WH; Lee WS; Hsueh PR
    J Microbiol Immunol Infect; 2017 Aug; 50(4):454-463. PubMed ID: 26454423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.
    Gao C; Tong J; Yu K; Sun Z; An R; Du Z
    Eur J Clin Pharmacol; 2016 Jul; 72(7):823-30. PubMed ID: 27023465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy of gatifloxacin with cefoperazone and cefoperazone-sulbactam against resistant strains of Pseudomonas aeruginosa.
    Sivagurunathan N; Krishnan S; Rao JV; Nagappa AN; Subrahmanyam VM; Vanathi BM
    J Med Microbiol; 2008 Dec; 57(Pt 12):1514-1517. PubMed ID: 19018022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Antimicrobial Activity of Various Cefoperazone/Sulbactam Products.
    Sheu MJ; Chen CC; Lu YC; Su BA; Zhang CC; Wang SS; Chuang YC; Tang HJ; Lai CC
    Antibiotics (Basel); 2020 Feb; 9(2):. PubMed ID: 32059590
    [No Abstract]   [Full Text] [Related]  

  • 8. Correlation Between Cefoperazone/Sulbactam MIC Values and Clinical Outcomes of Escherichia coli Bacteremia.
    Lin SY; Lu PL; Wu TS; Shie SS; Chang FY; Yang YS; Chiang TT; Wang FD; Ho MW; Chou CH; Liu JW; Shi ZY; Chuang YC; Tang HJ
    Infect Dis Ther; 2022 Oct; 11(5):1853-1867. PubMed ID: 35864347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter study on clinical outcomes and poor prognostic factors in patients with Klebsiella pneumoniae bacteremia receiving cefoperazone/sulbactam treatment.
    Chiang TT; Chiang MH; Tang HJ; Shi ZY; Ho MW; Chou CH; Lin SY; Lu PL; Wu TS; Shie SS; Liu JW; Chang FY; Chuang YC; Wang FD; Yang YS
    Eur J Clin Microbiol Infect Dis; 2024 Jul; ():. PubMed ID: 38995342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Adjunctive Therapy with Intravenous Cefoperazone-Sulbactam for Ventilator-Associated Pneumonia Due to Carbapenem-Resistant
    Kanchanasuwan S; Kositpantawong N; Singkhamanan K; Hortiwakul T; Charoenmak B; Ozioma F N; Doi Y; Chusri S
    Infect Drug Resist; 2021; 14():1255-1264. PubMed ID: 33824595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae.
    Su J; Guo Q; Li Y; Wu S; Hu F; Xu S; Wang M
    J Antimicrob Chemother; 2018 Nov; 73(11):3176-3180. PubMed ID: 30099554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal Dose of Cefoperazone-Sulbactam for Acute Bacterial Infection in Patients with Chronic Kidney Disease.
    Chao CM; Lai CC; Lee CH; Tang HJ
    Antibiotics (Basel); 2022 Apr; 11(5):. PubMed ID: 35625254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro antibacterial activity of sulperazone on multi-resistant strains of bacteria from burn wounds].
    Xu W; Chen X
    Zhonghua Wai Ke Za Zhi; 1995 Jul; 33(7):390-2. PubMed ID: 8565723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis.
    Sagan O; Yakubsevitch R; Yanev K; Fomkin R; Stone E; Hines D; O'Donnell J; Miller A; Isaacs R; Srinivasan S
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31843995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant
    Niu T; Luo Q; Li Y; Zhou Y; Yu W; Xiao Y
    Antimicrob Resist Infect Control; 2019; 8():52. PubMed ID: 30886705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin.
    Schmalreck AF; Wildfeuer A
    Arzneimittelforschung; 1990 Oct; 40(10):1145-55. PubMed ID: 2291754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: A retrospective matched cohort study.
    Raz-Pasteur A; Liron Y; Amir-Ronen R; Abdelgani S; Ohanyan A; Geffen Y; Paul M
    J Glob Antimicrob Resist; 2019 Jun; 17():168-172. PubMed ID: 30557685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study.
    Wang W; Liu Y; Yu C; Tan J; Xiong W; Dong D; Li S; Zhang R; Li J; Wu Y; Zong Z; Su N; Zou K; Wu G; Sun X
    Expert Opin Drug Saf; 2020 Mar; 19(3):339-347. PubMed ID: 31914329
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized Noninferiority Trial of Cefoperazone-Sulbactam versus Cefepime in the Treatment of Hospital-Acquired and Healthcare-Associated Pneumonia.
    Liu JW; Chen YH; Lee WS; Lin JC; Huang CT; Lin HH; Liu YC; Chuang YC; Tang HJ; Chen YS; Ko WC; Lu MC; Wang FD
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous determination of ampicillin, cefoperazone, and sulbactam in pharmaceutical formulations by HPLC with beta-cyclodextrin stationary phase.
    Tsou TL; Huang YC; Lee CW; Lee AR; Wang HJ; Chen SH
    J Sep Sci; 2007 Oct; 30(15):2407-13. PubMed ID: 17685376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.